Compound profile
KPV
EmergingAlso known as: Lys-Pro-Val · α-MSH(11-13)
The smallest active fragment of alpha-MSH (just three amino acids), studied almost entirely in mouse models of inflammatory bowel disease as an anti-inflammatory candidate. A clear example of a peptide with real preclinical mechanism data but essentially no human trials.
Overview
KPV is about as minimal as an active peptide gets: just three amino acids, lysine, proline, and valine, strung together. Despite its small size, it is not an incidental fragment. It corresponds to positions 11 through 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a larger hormone involved in pigmentation and immune regulation, and it turns out to retain a meaningful piece of that parent hormone's biological activity.
Specifically, KPV keeps alpha-MSH's anti-inflammatory effects while losing the pigmentation-related effects that come from activating melanocortin receptors more broadly. That separation is what makes it interesting to researchers: a way to potentially get an anti-inflammatory signal without the skin-darkening and other melanocortin receptor side effects that come with using the full hormone or receptor agonists like Melanotan II.
Almost the entire evidence base for KPV comes from mouse models of inflammatory bowel disease, chemically or immunologically induced colitis in laboratory mice. It has essentially no presence in human clinical trials. That makes it a clear example of a peptide with real, mechanistically interesting preclinical data that has not yet been tested in the way that would be needed to know whether any of it applies to people.
Mechanism (plain language)
Inhibits NF-kB and MAP kinase inflammatory signaling inside intestinal epithelial and immune cells, and is actively transported into those cells by the PepT1 di/tripeptide transporter, which is upregulated in inflamed colon tissue.
How it works
KPV's mechanism runs through inflammatory signaling inside cells rather than through the classic melanocortin receptors that the rest of the alpha-MSH molecule uses. Research describes it inhibiting NF-kB, a transcription factor that switches on a large number of inflammatory genes, and dampening MAP kinase signaling, another major inflammatory pathway, inside intestinal epithelial and immune cells. In some laboratory models, KPV has been reported to reduce NF-kB activation by a substantial margin.
What makes this mechanism unusual is how KPV gets into cells in the first place. Rather than triggering a receptor on the outside of the cell, KPV is actively transported directly into cells by PepT1, a transporter normally used to shuttle small peptide fragments of digested protein across the gut lining. PepT1 is notably upregulated in inflamed colon tissue, meaning the transporter that carries KPV into cells becomes more active precisely in the tissue where the peptide's anti-inflammatory effect would be most useful, a convenient overlap that researchers have highlighted as part of why it works well in gut inflammation models specifically.
What research suggests
Mouse models of colitis (DSS and cell-transfer models) report reduced inflammation, faster weight regain, and rescue from severe colitis when treated with KPV, with newer work exploring targeted nanoparticle delivery to improve oral bioavailability.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Reduced colitis severity in mouse models
KPV reduced inflammation across multiple mouse models of colitis, including chemically induced (DSS) and cell-transfer models of inflammatory bowel disease.
Faster recovery of body weight in animal studies
Mice treated with KPV in colitis models showed faster weight regain, a standard marker of recovery in these experiments.
Rescue effect in severe disease models
One study reported KPV rescued genetically susceptible (MC1R-deficient) mice from otherwise fatal colitis.
Targeted cellular entry via PepT1
The peptide's use of the PepT1 transporter, which is upregulated specifically in inflamed gut tissue, is being explored as a way to concentrate its effect where inflammation is present.
Uncertainties & risks
All meaningful efficacy data is in mice; there are no published human IBD trials of KPV specifically. Extrapolating rodent colitis results to human gut-health or skin-repair claims is a significant, unsupported leap at this stage.
The central limitation with KPV is straightforward: essentially all of the efficacy data is in mice, not people. There are no published human trials of KPV for inflammatory bowel disease or any other condition, which means claims about its usefulness for human gut health or skin repair are extrapolations from rodent colitis models rather than demonstrated effects. That is a substantial leap, since results in mouse models of induced colitis do not reliably predict what will happen in the much more complex and heterogeneous reality of human inflammatory bowel disease. Newer preclinical work has explored nanoparticle and other targeted delivery systems to improve KPV's oral bioavailability, which points to the fact that even within animal research, getting the peptide to work as an oral therapy is still an active engineering problem, not a solved one. As an unregulated research chemical, product purity and accurate dosing are also practical concerns independent of the underlying biology. Anyone considering KPV should be clear that they are relying on mouse data for a peptide that has not been tested in a human clinical trial.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.